

GIP-Dependent Expression of Hypothalamic Genes

S. AMBATI¹, J. DUAN¹, D. L. HARTZELL¹, Y.-H. CHOI³, M. A. DELLA-FERA¹,
C. A. BAILE^{1,2}

¹Department of Animal and Dairy Science, University of Georgia, Athens, USA, ²Department of Foods and Nutrition, University of Georgia, Athens, USA, ³Department of Animal Science and Institute of Agriculture & Life Sciences, Gyeongsang National University, Jinju, Korea

Received January 14, 2011

Accepted September 1, 2011

On-line October 12, 2011

Summary

GIP (glucose dependent insulintrophic polypeptide), originally identified as an incretin peptide synthesized in the gut, has recently been identified, along with its receptors (GIPR), in the brain. Our objective was to investigate the role of GIP in hypothalamic gene expression of biomarkers linked to regulating energy balance and feeding behavior related neurocircuitry. Rats with lateral cerebroventricular cannulas were administered 10 µg GIP or 10 µl artificial cerebrospinal fluid (aCSF) daily for 4 days, after which whole hypothalami were collected. Real time Taqman™ RT-PCR was used to quantitatively compare the mRNA expression levels of a set of genes in the hypothalamus. Administration of GIP resulted in up-regulation of hypothalamic mRNA levels of AVP (46.9±4.5 %), CART (25.9±2.7 %), CREB1 (38.5±4.5 %), GABRD (67.1±11 %), JAK2 (22.1±3.6 %), MAPK1 (33.8±7.8 %), NPY (25.3±5.3 %), OXT (49.1±5.1 %), STAT3 (21.6±3.8 %), and TH (33.9±8.5 %). In a second experiment the same set of genes was evaluated in GIPR^{-/-} and GIPR^{+/-} mice to determine the effect of lack of GIP stimulation on gene expression. In GIPR^{-/-} mice expressions of the following genes were down-regulated: AVP (27.1±7.5 %), CART (28.3±3.7 %), OXT (25.2±5.8 %), PTGES (23.9±4.5 %), and STAT3 (8.8±2.3 %). These results suggest that AVP, CART, OXT and STAT3 may be involved in energy balance-related hypothalamic circuits affected by GIP.

Key words

GIP receptor knockout • ICV administration • mRNA expression • Rats • Mice

Corresponding author

C. A. Baile, 444 Rhodes Center, University of Georgia, Athens GA 30602-2771, USA. Fax: (706) 542-7925. E-mail: cbaile@uga.edu

Introduction

Gastric inhibitory polypeptide (GIP) is a 42 amino acid peptide hormone, synthesized by K cells in the intestinal epithelium (Buchan *et al.* 1978) and released into the circulation in response to nutrient ingestion. It was renamed glucose dependent insulintrophic polypeptide, reflecting its important role as a hormone in gut physiology. GIP stimulates insulin secretion, and potentiates the action of insulin in adipose tissue and other target tissues (Moens *et al.* 1996, Yip and Wolfe 2000, Wideman and Kieffer 2004). GIP receptors were reported to be present in the pancreas, gut, adipose tissue, adrenal cortex and heart, and pituitary, as well as in several brain regions, including the cerebral cortex, hippocampus, hypothalamus and olfactory bulb (Usdin *et al.* 1993, Kaplan and Vigna 1994). Expression of GIP has also been reported in these brain regions (Nyberg *et al.* 2005, Sondhi *et al.* 2006).

The secretin family of peptides, of which GIP is a member, have been reported to be involved in a variety of brain functions such as neuro-modulation, neurogenesis, brain development, cell-cycle regulation, differentiation, and cell death as well as in regulation of food intake, body weight and body temperature (Sherwood *et al.* 2000, Nyberg *et al.* 2005). GIP also appears to have a role in bone metabolism, with GIP receptor knockout (GIPR^{-/-}) mice exhibiting reduced bone mass, whereas transgenic mice with GIP overexpression have increased bone mass (Ding *et al.* 2008).

GIP regulates lipid metabolism and storage (Holst 2004) partly through its effect on insulin secretion

and the resulting increased uptake and incorporation of glucose into lipids, as well as through direct effects in adipose tissue (Wasada 1981, Hauner *et al.* 1988, Yip and Wolfe 2000, Wideman and Kieffer 2004). GIPR^{-/-} mice were found to be resistant to diet-induced obesity and insulin resistance, and GIP has been considered as a potential pharmaceutical target in the treatment of diabetes, obesity and other metabolic disorders (Miyawaki *et al.* 2002, Kieffer 2003).

The objective of this study was to determine whether central administration of GIP altered expression of genes known to be involved in regulation of food intake and body energy balance and whether GIP receptor deficiency would result in opposite changes in expression of some or all of those genes. We report that GIP administered centrally to rats reduced body weight gain and induced changes in several genes involved in energy balance regulation. Furthermore, we identified a subset of those genes showing the opposite changes in expression in GIPR^{-/-} mice compared to GIPR^{+/?} mice.

Material and Methods

Male Sprague-Dawley rats (250-274 g) purchased from Harlan, Inc. (Indianapolis, IN) were used in the experiments 1 and 2. Ten week old C57BL/6 GIPR^{+/?} (n=20) and GIPR^{-/-} mice (n=18) were obtained from Dr. Carlos Isales (Medical College of Georgia). Two pairs of homozygous mice (GIPR^{-/-}) with targeted disruptions of exon 4 and 5 of the GIPR gene were originally obtained from the laboratory of Dr. Yuichiro Yamada (Department of Metabolism and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan), from which a breeding colony was established. The GIPR knockout mice were generated, bred, and maintained in the C57BL/6 line (Miyawaki *et al.* 1999). These mice were bred and maintained on a C57BL/6 genetic background in Dr. Isales' facility. Mice were kept four animals/cage, at 25 °C with a 12/12 h light/dark cycle. They had free access to a standard diet (Harlan TakLad Rodent Diet (W) 8604) and water *ad libitum*. Rats were housed singly in a light (12 h on/12h off) – and temperature controlled environment (22±1 °C, humidity 50 %). Rats were fed standard rodent chow and provided with water *ad libitum*.

Effect of icv injection of GIP on food intake and weight gain in rats

Rats were implanted with chronic lateral

cerebroventricular cannulas as previously described (Choi *et al.* 2003), and after recovery from surgery, they were randomly assigned to four groups (n=8). Control rats were administered 10 µl artificial cerebrospinal fluid (aCSF) at 24-hour intervals for 4 days. The GIP treated rats were administered 0.1, 1.0 or 10 µg/day GIP in 10 µl aCSF for 4 days. The injections were carried out using an injector cannula (C313I, Plastics One, Roanoke, VA) that protruded 1.1 mm below the tip of the guide cannula and that was connected to a Gilmont microsyringe by way of polyethylene tubing (PE20 Intramedic, Cat. #427406, BD, Sparks, MD). Food and water were available *ad libitum*. Food intake was measured daily and rats were weighed daily. All experiments and surgical procedures were performed in accordance with the guidelines approved by the Institutional Animal Care and Use Committee of the University of Georgia. Twenty-four hours after the last icv injection, rats were killed by decapitation after a brief exposure to carbon dioxide.

Effect of icv injection of GIP on gene expression in rats

Rats were implanted with chronic lateral cerebroventricular cannulas as previously described (Choi *et al.* 2003), and after recovery from surgery, they were randomly divided into two groups (n=8). Control rats were administered 10 µl artificial cerebrospinal fluid (aCSF) at 24-hour intervals for 4 days; the GIP-treated rats were administered 10 µg/day GIP in 10 µl aCSF for 4 days. The dose used was selected based on the results of the previous experiment. Food and water were available *ad libitum*. Twenty-four hours after the last injection rats were killed by decapitation after a brief exposure to carbon dioxide. The brains were removed rapidly after decapitation and immediately frozen by placing them on plastic cassettes on top of powdered dry ice. Once completely frozen, they were stored at -80 °C. The brains were thawed to -20 °C before the hypothalamic dissection.

Hypothalamic gene expression in GIPR^{-/-} mice

In this experiment the hypothalamic gene expression profile of GIPR^{+/?} mice was compared to that from GIPR^{-/-} mice. Mice were deeply anesthetized with CO₂ before decapitation. The brains were removed rapidly after decapitation and immediately frozen on powdered dry ice. They were stored at -80 °C. The brains were thawed to -20 °C before the hypothalamic dissection. Hypothalamic blocks from two mice of the same group were randomly pooled together for RNA extraction.

Extraction of total RNA, reverse transcription (RT) and real-time PCR

Total hypothalamic RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's protocol. The integrity of the total RNA obtained from all the samples were verified using the RNA 6000 Nano Assay and the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). The RT reaction was performed on 100 ng of total RNA per sample in a 20 μ l reaction mixture using the cDNA Archive Kit with MultiScribe™ Reverse Transcriptase (Applied Biosystems, Inc., ABI, Foster City, CA) according to the manufacturer's instructions. Reactions were incubated initially at 25 °C for 10 min and subsequently at 37 °C for 120 min. Quantitative PCR (Taqman™) assays chosen for the transcripts to be evaluated were from Assays-On-Demand™ (ABI), a pre-validated library of QPCR assays and were incorporated into 384-well MicroFluidic™ cards. All of the oligonucleotide primer and fluorogenic probe sets for Taqman™ real time PCR in rats and mice were from ABI (Table 1). Two μ l of the cDNA along with 50 μ l of 2 x PCR master mixes were loaded into respective channels on the microfluidic card followed by a brief centrifugation. The card was then sealed and real-time PCR and relative quantification were carried out on the ABI PRISM 7900 Sequence Detection System. The cycle conditions were: 94.5 °C for 15 min, followed by 40 cycles of 97 °C for 30 s, 59.7 °C for 1 min. Data were analyzed using Sequence Detection Systems software (Applied Biosystems) and the Relative Quantification (RQ) method, which represents the fold difference of mRNA level in rats treated with GIP relative to rats treated with control or the GIPR^{-/-} mice relative to GIPR^{+/?} mice. Preliminary experiments were carried out to determine the most appropriate endogenous control gene to use to correct for differences in the amounts of total RNA added to each reaction. For the rat experiment, mRNA expressions were normalized with 18 S as an endogenous control to correct the differences in the amount of total RNA added to each reaction. β -ACT was used as endogenous control in the mouse experiment. The ΔC_T values were calculated initially using C_T for a specific gene mRNA minus C_T for 18 S mRNA (in rats) and β -ACT (in the mice) in the sample. The mean mRNA expressions from the rats treated with GIP were compared with those from the α CSF treated rats and mRNA expressions from the GIPR^{-/-} mice were compared

to those from the GIPR^{+/?} mice using the formula: Relative Quantification (RQ) = $2^{-\Delta\Delta C_T}$ ($\Delta\Delta C_T$ is the average control group ΔC_T values minus the average experimental group ΔC_T values, and $\Delta\Delta C_T$ of 1 equates to a two-fold difference in starting amount of cDNA). The relative quantification values from each gene were used to compare the hypothalamic gene expression between two groups.

Statistical analysis

Food intake and body weight gain data were analyzed using the general linear model ANOVA (Statistica v. 7.1; StatSoft, Inc., Tulsa, OK). Fishers LSD test was used to determine significance among means, with $p < 0.05$ considered significant. Data are expressed as means \pm S.E.M.

Gene expression data are shown as means \pm S.E.M. of relative quantification (RQ) values from the Sequence Detection System (SDS, ABI-Perkin Elmer, Foster City, CA) files for all the genes. Statistical significance was assessed by general linear model ANOVA for multiple comparisons between the means for the different treatment/genotype groups. The Benjamini-Hochberg procedure was used to control for false discovery rate. A $p < 0.05$ was considered to be significant. Multivariate analysis between genes was performed with Pearson correlation.

Results

Effect of icv administration of GIP on food intake and body weight of rats

GIP administered icv for 4 days in rats had no effect on food intake (data not shown). However, 10 μ g/day GIP caused a significant loss of body weight compared to control and the other GIP treatments (Fig. 1). This dose was then selected for determination of effects on hypothalamic gene expression.

Effect of icv administration of GIP on hypothalamic gene expression in rats

Increased hypothalamic mRNA expression levels were found for AVP (46.9 \pm 4.5 %), CART (25.9 \pm 2.7 %), CREB1 (38.5 \pm 4.5 %), GABRD (67.1 \pm 11 %), JAK2 (22.1 \pm 3.6 %), MAPK1 (33.8 \pm 7.8 %), NPY (25.3 \pm 5.3 %), OXT (49.1 \pm 5.1 %), STAT3 (21.6 \pm 3.8 %), and TH (33.9 \pm 8.5 %) after 4 days of icv injections of 10 μ g/day GIP in rats (Table 2).

Table 1. Probes used for real time PCR.

Gene symbol	Gene name	Rat ABI assay ID	Mice ABI assay ID	Function
<i>18S</i>		4342379-18S	-----	House-keeping gene
<i>β-ACT</i>	actin, beta	-----	Mm00607939_s1	House-keeping gene
<i>AVP</i>	arginine vasopressin	Rn00566449_m1	Mm00437761_g1	Neuroendocrine and feeding regulation (Bray 2000, Landgraf 2006)
<i>CART</i>	cocaine and amphetamine regulated transcript	Rn00567382_m1	Mm00489086_m1	Energy balance, bone metabolism, anxiety (Asakawa <i>et al.</i> 2001, Kong <i>et al.</i> 2003, Tian <i>et al.</i> 2004, Wortley <i>et al.</i> 2004, Eleftheriou <i>et al.</i> 2005)
<i>CREB1</i>	cAMP responsive element binding protein 1	Rn00578829_g1	Mm00501607_m1	Learning, memory, anxiety, feeding related circuits (Carlezon <i>et al.</i> 2005, Duman and Duman 2005, Georgescu <i>et al.</i> 2005, Altarejos and Montminy 2011)
<i>MAPK1</i>	mitogen activated protein kinase 1	Rn00587719_m1	Mm00442479_m1	Sympathetic activation, leptin and insulin feeding circuits, circadian rhythm (Coogan and Piggins 2004, Hegyi <i>et al.</i> 2004, Rahmouni <i>et al.</i> 2004, Ambati <i>et al.</i> 2007)
<i>OXT</i>	oxytocin	Rn00564446_g1	Mm00726655_s1	social behaviors, anxiety, feeding behavior (Bale <i>et al.</i> 2001, Sabatier <i>et al.</i> 2007, Veenema and Neumann 2008)
<i>SCT</i>	secretin	Rn00575360_g1	Mm00441235_g1	Feeding behavior, autism (Ambati <i>et al.</i> 2007, 2009, Lee <i>et al.</i> 2010, Cheng <i>et al.</i> 2011)
<i>TH</i>	tyrosine hydroxylase	Rn00562500_m1	Mm00447546_m1	Feeding, reward (Ambati <i>et al.</i> 2007, 2009, Lee <i>et al.</i> 2010)
<i>GABRD</i>	gamma-aminobutyric acid A receptor, delta	Rn00568740_m1	Mm00433476_m1	Inhibitory neurotransmitter, cognition, speech, feeding behavior (Windpassinger <i>et al.</i> 2002, Ambati <i>et al.</i> 2009)
<i>JAK2</i>	Janus kinase 2	Rn00580452_m1	Mm00434561_m1	leptin signaling (Sandberg <i>et al.</i> 2004, Villanueva and Myers 2008)
<i>NPY</i>	neuropeptide Y	Rn00561681_m1	Mm00445771_m1	Feeding behavior (Kalra <i>et al.</i> 1991, Kalra and Kalra 2003)
<i>POMC</i>	pro-opiomelanocortin	Rn00595020_m1	Mm00435874_m1	Feeding behavior (Boston 2001, Li <i>et al.</i> 2003)
<i>PTGES</i>	prostaglandin E synthase	Mm00456961_m1	Mm00452105_m1	Inflammation, feeding behavior (Turnbull and Rivier 1996, Ohinata <i>et al.</i> 2008, Ambati <i>et al.</i> 2009)
<i>SOCS3</i>	suppressor of cytokine signaling 3	Rn00585674_sl	Mm00545913_sl	Leptin signaling, neuroimmuneendocrine modulator (Auernhammer <i>et al.</i> 2000, Morris and Rui 2009)
<i>STAT3</i>	signal transducer and activator of transcription 3	Rn00562562_m1	Mm00456961_m1	Signal transduction in feeding related circuits (Carvalho <i>et al.</i> 2001, Zhao <i>et al.</i> 2002, Hommel <i>et al.</i> 2006, Gao <i>et al.</i> 2007)

*POMC1, mouse; POMC2, rat.




Fig. 1. Weight gain/loss in rats treated daily for 4 days with control (aCSF) or 10 μ g/d GIP administered into the lateral cerebral ventricle. Data are means \pm S.E.M. Means not denoted with a common superscript are different, ^{ab} $p < 0.05$.

Correlation between CREB1 and MAPK1 mRNA expression levels in GIP-treated rats

The mRNA levels of both CREB1 and MAPK1 showed a proportional increase with a positive correlation (Correlation coefficient, $r = 0.87$, $p < 0.001$) in the hypothalamus of GIP-treated rats.

Hypothalamic gene expression in $GIPR^{-/-}$ and $GIPR^{+/?}$ mice

The hypothalamic mRNA levels of some biomarkers were lower in hypothalami of $GIPR^{-/-}$ mice when compared with those of wild-type controls. Relative to $GIPR^{+/?}$ mice, expression levels of hypothalamic mRNAs of AVP ($27.1 \pm 7.5\%$), CART ($28.3 \pm 3.7\%$), OXT ($25.2 \pm 5.8\%$), PTGES ($23.9 \pm 4.5\%$), and STAT3 ($8.8 \pm 2.3\%$) in $GIPR^{-/-}$ mice were down-regulated (Table 2).

Hypothalamic mRNA expression of MAPK1 ($38.2 \pm 4.0\%$, $p < 0.01$) and NPY ($31.6 \pm 8.5\%$, $p < 0.01$) was increased in $GIPR^{-/-}$ mice relative to $GIPR^{+/?}$ mice.

Discussion

GIP is considered to be one of the principle incretin factors of the enteroinsular axis system which has been implicated to play a critical role in the pathogenesis of diabetes and obesity (Wideman and Kieffer 2004, Yip and Wolfe 2000). The current study was designed to investigate the alterations in expression of hypothalamic genes involved in feeding behavior and energy balance regulation in rats treated icv with GIP and in $GIPR$ deficient mice.

AVP is suggested to trigger a variety of effects relating to regulation of water, glucose and electrolytes and

neuroendocrine functions and may also play a role in energy balance regulation (Bray 2000, Landgraf 2006). The structurally-related neuropeptide oxytocin (OXT) has also been implicated in feeding, complex social behaviors and anxiety-associated behaviors (Bale *et al.* 2001, Sabatier *et al.* 2007). Higher levels of AVP and OXT mRNA expression were found following icv GIP treatment in rats. Furthermore, both AVP and OXT expressions were lower in $GIPR^{-/-}$ mice, thus suggesting that these hypothalamic neuropeptides may mediate GIP-induced behavioral changes related to energy balance regulation.

Cocaine- and amphetamine-regulated transcript (CART) is highly expressed in the hypothalamus, particularly in the paraventricular (PVN) and arcuate (ARC) nuclei (Couceyro *et al.* 1997), which are critical in the regulation of energy homeostasis. CART was originally reported to be an anorectic neuropeptide, based on icv administration of CART(55-102) (Kristensen *et al.* 1998, Stanley *et al.* 2001) and on overexpression of CART after administration of recombinant adeno-associated virus (rAAV)-CART into the third ventricle in diet-induced obese rats (Qing and Chen, 2007). However, icv administration of CART is also associated with motor disturbances which may interfere with feeding (Aja *et al.* 2001). In contrast, direct administration of CART (55-102) into discrete hypothalamic nuclei (Abbott *et al.* 2001) and over-expression of CART in the ARC (Kong *et al.* 2003) and PVN (Smith *et al.* 2008) have been shown to increase food intake and weight gain.

In our study hypothalamic CART expression was increased in rats treated icv with GIP and decreased in mice deficient in $GIPR$. Although GIP did not affect food intake in the rats, it did cause weight loss, and a previous study has shown that overexpression of GIP in mice resulted in enhanced locomotor behavior and no increase in anxiety behavior (Ding *et al.* 2006). Thus, the changes in whole hypothalamic CART expression may be related to the effect of GIP on energy balance regulation, but probably not through changes in anxiety or locomotor behavior.

STAT proteins are a family of cytoplasmic transcription factors activated by tyrosine phosphorylation and dimerization in response to cytokines, growth factors and other extracellular ligands (Dandoy-Dron *et al.* 1995, Sano *et al.* 1999). In particular, STAT3 has been shown to play an important role in the regulation of energy balance. STAT3 is a known downstream component of both leptin and ciliary neurotrophic factor (CNTF) action (Hubschle *et al.* 2001, Lambert *et al.* 2001). Mice with STAT3 deletion

Table 2. Hypothalamic mRNA expression (mean \pm S.E.M.) of hypothalamic genes in GIPR^{+/?} and GIPR^{-/-} mice* and in rats** after 4 days ICV injection of 0 or 10 μ g/d GIP.

Gene	GIPR ^{+/?} mice	GIPR ^{-/-} mice	Rats (0 μ g/d GIP ICV)	Rats (10 μ g/d GIP ICV)
<i>AVP</i>	0.85 \pm 0.09 ^a	0.62 \pm 0.08 ^b	0.78 \pm 0.06 ^x	1.14 \pm 0.03 ^y
<i>CART</i>	0.7 \pm 0.05 ^a	0.50 \pm 0.03 ^b	0.97 \pm 0.07 ^a	1.22 \pm 0.02 ^b
<i>CREB1</i>	1.08 \pm 0.02	1.04 \pm 0.02	0.81 \pm 0.04 ^x	1.12 \pm 0.03 ^y
<i>GABRD</i>	1.44 \pm 0.1	1.52 \pm 0.05	0.89 \pm 0.03 ^x	1.49 \pm 0.1 ^y
<i>JAK2</i>	1.16 \pm 0.04	1.2 \pm 0.03	0.84 \pm 0.06 ^a	1.03 \pm 0.03 ^b
<i>MAPK1</i>	1.31 \pm 0.06 ^x	1.82 \pm 0.07 ^y	0.85 \pm 0.06 ^a	1.14 \pm 0.06 ^b
<i>NPY</i>	1.29 \pm 0.06 ^a	1.7 \pm 0.11 ^b	0.75 \pm 0.06 ^a	0.94 \pm 0.05 ^b
<i>OXT</i>	0.8 \pm 0.06 ^a	0.6 \pm 0.06 ^b	0.85 \pm 0.09 ^x	1.27 \pm 0.04 ^y
<i>POMC</i>	0.85 \pm 0.09	0.66 \pm 0.14	0.75 \pm 0.07	0.85 \pm 0.04
<i>PTGES</i>	1.17 \pm 0.07 ^a	0.89 \pm 0.04 ^b	0.93 \pm 0.06	1.08 \pm 0.06
<i>SCT</i>	1.1 \pm 0.15	0.83 \pm 0.10	0.85 \pm 0.08	1.14 \pm 0.01
<i>SOCS3</i>	1.32 \pm 0.15	0.84 \pm 0.06	0.90 \pm 0.07	0.95 \pm 0.04
<i>STAT3</i>	1.15 \pm 0.03 ^a	1.05 \pm 0.03 ^b	0.79 \pm 0.06 ^a	0.96 \pm 0.03 ^b
<i>TH</i>	0.85 \pm 0.07	0.7 \pm 0.04	0.76 \pm 0.09 ^a	1.01 \pm 0.06 ^b

*Data are normalized to β -ACT values; **Data are normalized to the 18S values; means with different superscripts are different ^{ab} $p < 0.05$; ^{xy} $p < 0.01$.

in leptin receptor positive neurons of the hypothalamus become hyperphagic after weaning, have increased body weight and body fat, and exhibit impaired glucose tolerance (Cui *et al.* 2004). While phosphorylation levels of STAT3 are believed to be more critical than variations of mRNA level, our previous study showed that mRNA levels of STAT3 in the arcuate nucleus/median eminence of the hypothalamus were significantly up-regulated in rats with ICV treatment of leptin or CNTF (Ambati *et al.* 2007). The results from the present study show increased expression of STAT3 in the hypothalamus of rats treated icv with GIP and decreased expression of hypothalamic STAT3 in mice deficient in GIPR. Thus, STAT3 may also be a downstream transcription factor involved in the central effect of GIP on energy balance regulation.

GABRD is a receptor for gamma-aminobutyric acid, an inhibitory neuropeptide involved in a number of hypothalamic and higher brain functions, including neuronal network development, cognition and speech (Windpassinger *et al.* 2002). CREB1 protein is a transcription factor and usually considered a marker of neuron activation (Zachariou *et al.* 2001). In rats treated icv with GIP, GABRD and CREB1 mRNA expression was increased, suggesting elevated neuronal activity as a response to GIP treatment. Interestingly, proportionate increase in mRNA expression levels of CREB1 and

MAPK1 in the hypothalamus of GIP-treated rats indicated a possible MAPK-1 signaling-dependent neuron activation by CREB1 (Pandey 2003, Euskirchen *et al.* 2004). CREB1 plays a regulatory role in the nervous system and is widely believed to promote neuronal survival, precursor proliferation and other neuronal-related functions (Rodriguez and Ferrer 2007). Phosphorylation of CREB1 through MAPK signaling is a critical event in the network of neuronal activation, neuronal proliferation, differentiation and synaptic function. Activation of this network also stimulates neurite outgrowth in the central nervous system and also in neuronal cell-lines (Ma'ayan *et al.* 2009). Furthermore, there is evidence that phosphorylation of CREB regulates NPY expression in the brain (Pandey 2003).

In conclusion, our data suggest that GIP and its receptor may be involved in energy balance regulation by the hypothalamus as evident by the changes in expression levels of genes such as AVP, CART, OXT, and STAT3.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

This work was supported in part by Georgia Research Alliance Eminent Scholar endowment held by CAB.

References

- ABBOTT CR, ROSSI M, WREN AM, MURPHY KG, KENNEDY AR, STANLEY SA, ZOLLNER AN, MORGAN DG, MORGAN I, GHATEI MA, SMALL CJ, BLOOM SR: Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei. *Endocrinology* **142**: 3457-3463, 2001.
- AJA S, SCHWARTZ GJ, KUHAR MJ, MORAN TH: Intracerebroventricular CART peptide reduces rat ingestive behavior and alters licking microstructure. *Am J Physiol Regul Integr Comp Physiol* **280**: R1613-R1619, 2001.
- ALTAREJOS JY, MONTMINY M: CREB and the CRTG co-activators: sensors for hormonal and metabolic signals. *Nat Rev Mol Cell Biol* **12**: 141-151, 2011.
- AMBATI S, DUAN J, CHOI YH, HARTZELL DL, DELLA-FERA MA, BAILE CA: ICV vs. VMH injection of leptin: Comparative effects on hypothalamic gene expression. *Behav Brain Res* **196**: 279-285, 2009.
- AMBATI S, DUAN J, DUFF E, CHOI YH, HARTZELL DL, DELLA-FERA MA, BAILE CA: Gene expression in arcuate nucleus of rats treated with leptin or ciliary neurotrophic factor. *Biofactors* **31**: 133-144, 2007.
- ASAKAWA A, INUI A, YUZURIHA H, NAGATA T, KAGA T, UENO N, FUJINO MA, KASUGA M: Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice. *Horm Metab Res* **33**: 554-558, 2001.
- AUERNHAMMER CJ, BOUSQUET C, CHESNOKOVA V, MELMED S: SOCS proteins: modulators of neuroimmunoendocrine functions. Impact on corticotroph LIF signaling. *Ann NY Acad Sci* **917**: 658-664, 2000.
- BALE TL, DAVIS AM, AUGER AP, DORSA DM, MCCARTHY MM: CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. *J Neurosci* **21**: 2546-2552, 2001.
- BOSTON BA: Pro-opiomelanocortin and weight regulation: from mice to men. *J Pediatr Endocrinol Metab* **14** (Suppl 6): 1409-1416, 2001.
- BRAY GA: Afferent signals regulating food intake. *Proc Nutr Soc* **59**: 373-384, 2000.
- BUCHAN AM, POLAK JM, CAPELLA C, SOLCIA E, PEARSE AG: Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. *Histochemistry* **56**: 37-44, 1978.
- CARLEZON WA JR, DUMAN RS, NESTLER EJ: The many faces of CREB. *Trends Neurosci* **28**: 436-445, 2005.
- CARVALHEIRA JB, SILOTO RM, IGNACCHITTI I, BRENELLI SL, CARVALHO CR, LEITE A, VELLOSO LA, GONTIJO JA, SAAD MJ: Insulin modulates leptin-induced STAT3 activation in rat hypothalamus. *FEBS Lett* **500**: 119-124, 2001.
- CHENG CY, CHU JY, CHOW BK: Central and peripheral administration of secretin inhibits food intake in mice through the activation of the melanocortin system. *Neuropsychopharmacology* **36**: 459-471, 2011.
- CHOI YH, LI C, PAGE K, WESTBY A, DELLA-FERA MA, LIN J, HARTZELL DL, BAILE CA: Melanocortin receptors mediate leptin effects on feeding and body weight but not adipose apoptosis. *Physiol Behav* **79**: 795-801, 2003.
- COOGAN AN, PIGGINS HD: MAP kinases in the mammalian circadian system--key regulators of clock function. *J Neurochem* **90**: 769-775, 2004.
- COUCEYRO PR, KOYLU EO, KUHAR MJ: Further studies on the anatomical distribution of CART by in situ hybridization. *J Chem Neuroanat* **12**: 229-241, 1997.
- CUI Y, HUANG L, ELEFTERIOU F, YANG G, SHELTON JM, GILES JE, OZ OK, POURBAHRAMI T, LU CY, RICHARDSON JA, KARSENTY G, LI C: Essential role of STAT3 in body weight and glucose homeostasis. *Mol Cell Biol* **24**: 258-269, 2004.
- DANDOY-DRON F, ITIER JM, MONTHIOUX E, BUCCHINI D, JAMI J: Tissue-specific expression of the rat insulin 1 gene in vivo requires both the enhancer and promoter regions. *Differentiation* **58**: 291-295, 1995.
- DING KH, SHI XM, ZHONG Q, KANG B, XIE D, BOLLAG WB, BOLLAG RJ, HILL W, WASHINGTON W, MI QS, INSOGNA K, CHUTKAN N, HAMRICK M, ISALES CM: Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. *J Bone Miner Res* **23**: 536-543, 2008.

- DING KH, ZHONG Q, XIE D, CHEN HX, DELLA-FERA MA, BOLLAG RJ, BOLLAG WB, GUJRAL R, KANG B, SRIDHAR S, BAILE C, CURL W, ISALES CM: Effects of glucose-dependent insulintropic peptide on behavior. *Peptides* **27**: 2750-2755, 2006.
- DUMAN CH, DUMAN RS: Neurobiology and treatment of anxiety: signal transduction and neural plasticity. *Handb Exp Pharmacol* **169**: 305-334, 2005.
- ELEFTERIOU F, AHN JD, TAKEDA S, STARBUCK M, YANG X, LIU X, KONDO H, RICHARDS WG, BANNON TW, NODA M, CLEMENT K, VAISSE C, KARSENTY G: Leptin regulation of bone resorption by the sympathetic nervous system and CART. *Nature* **434**: 514-520, 2005.
- EUSKIRCHEN G, ROYCE TE, BERTONE P, MARTONE R, RINN JL, NELSON FK, SAYWARD F, LUSCOMBE NM, MILLER P, GERSTEIN M, WEISSMAN S, SNYDER M: CREB binds to multiple loci on human chromosome 22. *Mol Cell Biol* **24**: 3804-3814, 2004.
- GAO Q, MEZEI G, NIE Y, RAO Y, CHOI CS, BECHMANN I, LERANTH C, TORAN-ALLERAND D, PRIEST CA, ROBERTS JL, GAO XB, MOBBS C, SHULMAN GI, DIANO S, HORVATH TL: Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. *Nat Med* **13**: 89-94, 2007.
- GEORGESCU D, SEARS RM, HOMMEL JD, BARROT M, BOLANOS CA, MARSH DJ, BEDNAREK MA, BIBB JA, MARATOS-FLIER E, NESTLER EJ, DILEONE RJ: The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. *J Neurosci* **25**: 2933-2940, 2005.
- HAUNER H, GLATTING G, KAMINSKA D, PFEIFFER EF: Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. *Ann Nutr Metab* **32**: 282-288, 1988.
- HEGYI K, FULOP K, KOVACS K, TOTH S, FALUS A: Leptin-induced signal transduction pathways. *Cell Biol Int* **28**: 159-169, 2004.
- HOLST JJ: On the physiology of GIP and GLP-1. *Horm Metab Res* **36**: 747-754, 2004.
- HOMMEL JD, TRINKO R, SEARS RM, GEORGESCU D, LIU ZW, GAO XB, THURMON JJ, MARINELLI M, DILEONE RJ: Leptin receptor signaling in midbrain dopamine neurons regulates feeding. *Neuron* **51**: 801-810, 2006.
- HUBSCHLE T, THOM E, WATSON A, ROTH J, KLAUS S, MEYERHOF W: Leptin-induced nuclear translocation of STAT3 immunoreactivity in hypothalamic nuclei involved in body weight regulation. *J Neurosci* **21**: 2413-2424, 2001.
- KALRA SP, DUBE MG, SAHU A, PHELPS CP, KALRA PS: Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. *Proc Natl Acad Sci USA* **88**: 10931-10935, 1991.
- KALRA SP, KALRA PS: Neuropeptide Y: a physiological orexigen modulated by the feedback action of ghrelin and leptin. *Endocrine* **22**: 49-56, 2003.
- KAPLAN AM, VIGNA SR: Gastric inhibitory polypeptide (GIP) binding sites in rat brain. *Peptides* **15**: 297-302, 1994.
- KIEFFER TJ: GIP or not GIP? That is the question. *Trends in pharmacological sciences* **24**: 110-112, 2003.
- KONG WM, STANLEY S, GARDINER J, ABBOTT C, MURPHY K, SETH A, CONNOLEY I, GHATEI M, STEPHENS D, BLOOM S: A role for arcuate cocaine and amphetamine-regulated transcript in hyperphagia, thermogenesis, and cold adaptation. *FASEB J* **17**: 1688-1690, 2003.
- KRISTENSEN P, JUDGE ME, THIM L, RIBEL U, CHRISTJANSEN KN, WULFF BS, CLAUSEN JT, JENSEN PB, MADSEN OD, VRANG N, LARSEN PJ, HASTRUP S: Hypothalamic CART is a new anorectic peptide regulated by leptin. *Nature* **393**: 72-76, 1998.
- LAMBERT PD, ANDERSON KD, SLEEMAN MW, WONG V, TAN J, HIJARUNGURU A, CORCORAN TL, MURRAY JD, THABET KE, YANCOPOULOS GD, WIEGAND SJ: Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. *Proc Natl Acad Sci USA* **98**: 4652-4657, 2001.
- LANDGRAF R: The involvement of the vasopressin system in stress-related disorders. *CNS Neurol Disord Drug Targets* **5**: 167-179, 2006.

- LEE AK, MOJTAHED-JABERI M, KYRIAKOU T, ALDECOA-OTALORA ASTARLOA E, ARNO M, MARSHALL NJ, BRAIN SD, O'DELL SD: Effect of high-fat feeding on expression of genes controlling availability of dopamine in mouse hypothalamus. *Nutrition* **26**: 411-422, 2010.
- LI G, MOBBS CV, SCARPACE PJ: Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. *Diabetes* **52**: 1951-1957, 2003.
- MA'AYAN A, JENKINS SL, BARASH A, IYENGAR R: Neuro2A differentiation by Galphai/o pathway. *Sci Signal* **2**: cm1, 2009.
- MIYAWAKI K, YAMADA Y, BAN N, IHARA Y, TSUKIYAMA K, ZHOU H, FUJIMOTO S, OKU A, TSUDA K, TOYOKUNI S, HIAI H, MIZUNOYA W, FUSHIKI T, HOLST JJ, MAKINO M, TASHITA A, KOBARA Y, TSUBAMOTO Y, JINNOUCHI T, JOMORI T, SEINO Y: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nat Med* **8**: 738-742, 2002.
- MIYAWAKI K, YAMADA Y, YANO H, NIWA H, BAN N, IHARA Y, KUBOTA A, FUJIMOTO S, KAJIKAWA M, KUROSU A, TSUDA K, HASHIMOTO H, YAMASHITA T, JOMORI T, TASHIRO F, MIYAZAKI J, SEINO Y: Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. *Proc Natl Acad Sci USA* **96**: 14843-14847, 1999.
- MOENS K, HEIMBERG H, FLAMEZ D, HUYPENS P, QUARTIER E, LING Z, PIPELEERS D, GREMLICH S, THORENS B, SCHUIT F: Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. *Diabetes* **45**: 257-261, 1996.
- MORRIS DL, RUI L: Recent advances in understanding leptin signaling and leptin resistance. *Am J Physiol Endocrinol Metab* **297**: E1247-E1259, 2009.
- NYBERG J, ANDERSON MF, MEISTER B, ALBORN AM, STROM AK, BREDERLAU A, ILLERSKOG AC, NILSSON O, KIEFFER TJ, HIETALA MA, RICKSTEN A, ERIKSSON PS: Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. *J Neurosci* **25**: 1816-1825, 2005.
- OHINATA K, TAKAGI K, BIYAJIMA K, FUJIWARA Y, FUKUMOTO S, EGUCHI N, URADE Y, ASAKAWA A, FUJIMIYA M, INUI A, YOSHIKAWA M: Central prostaglandin D(2) stimulates food intake via the neuropeptide Y system in mice. *FEBS Lett* **582**: 679-684, 2008.
- PANDEY SC: Anxiety and alcohol abuse disorders: a common role for CREB and its target, the neuropeptide Y gene. *Trends Pharmacol Sci* **24**: 456-460, 2003.
- QING K, CHEN Y: Central CART gene delivery by recombinant AAV vector attenuates body weight gain in diet-induced-obese rats. *Regul Pept* **140**: 21-26, 2007.
- RAHMOUNI K, MORGAN DA, MORGAN GM, LIU X, SIGMUND CD, MARK AL, HAYNES WG: Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. *J Clin Invest* **114**: 652-658, 2004.
- RODRIGUEZ A, FERRER I: Expression of transcription factors CREB and c-Fos in the brains of terminal Creutzfeldt-Jakob disease cases. *Neurosci Lett* **421**: 10-15, 2007.
- SABATIER N, ROWE I, LENG G: Central release of oxytocin and the ventromedial hypothalamus. *Biochem Soc Trans* **35**: 1247-1251, 2007.
- SANDBERG EM, MA X, VONDERLINDEN D, GODENY MD, SAYESKI PP: Jak2 tyrosine kinase mediates angiotensin II-dependent inactivation of ERK2 via induction of mitogen-activated protein kinase phosphatase 1. *J Biol Chem* **279**: 1956-1967, 2004.
- SANO S, ITAMI S, TAKEDA K, TARUTANI M, YAMAGUCHI Y, MIURA H, YOSHIKAWA K, AKIRA S, TAKEDA J: Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. *EMBO J* **18**: 4657-4668, 1999.
- SHERWOOD NM, KRUECKL SL, MCRORY JE: The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. *Endocr Rev* **21**: 619-670, 2000.
- SMITH KL, GARDINER JV, WARD HL, KONG WM, MURPHY KG, MARTIN NM, GHATEI MA, BLOOM SR: Overexpression of CART in the PVN increases food intake and weight gain in rats. *Obesity (Silver Spring)* **16**: 2239-2244, 2008.

- SONDHI S, CASTELLANO JM, CHONG VZ, ROGOZA RM, SKOBLENICK KJ, DYCK BA, GABRIELE J, THOMAS N, KI K, PRISTUPA ZB, SINGH AN, MACCRIMMON D, VORUGANTI P, FOSTER J, MISHRA RK: cDNA array reveals increased expression of glucose-dependent insulintropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects. *Pharmacogenomics J* **6**: 131-140, 2006.
- STANLEY SA, SMALL CJ, MURPHY KG, RAYES E, ABBOTT CR, SEAL LJ, MORGAN DG, SUNTER D, DAKIN CL, KIM MS, HUNTER R, KUCHAR M, GHATEI MA, BLOOM SR: Actions of cocaine- and amphetamine-regulated transcript (CART) peptide on regulation of appetite and hypothalamo-pituitary axes in vitro and in vivo in male rats. *Brain Res* **893**: 186-194, 2001.
- TIAN DR, LI XD, SHI YS, WAN Y, WANG XM, CHANG JK, YANG J, HAN JS: Changes of hypothalamic alpha-MSH and CART peptide expression in diet-induced obese rats. *Peptides* **25**: 2147-2153, 2004.
- TURNBULL AV, RIVIER C: Corticotropin-releasing factor, vasopressin, and prostaglandins mediate, and nitric oxide restrains, the hypothalamic-pituitary-adrenal response to acute local inflammation in the rat. *Endocrinology* **137**: 455-463, 1996.
- USDIN TB, MEZEY E, BUTTON DC, BROWNSTEIN MJ, BONNER TI: Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. *Endocrinology* **133**: 2861-2870, 1993.
- VEENEMA AH, NEUMANN ID: Central vasopressin and oxytocin release: regulation of complex social behaviours. *Prog Brain Res* **170**: 261-276, 2008.
- VILLANUEVA EC, MYERS MG JR: Leptin receptor signaling and the regulation of mammalian physiology. *Int J Obes (Lond)* **32** (Suppl 7): S8-S12, 2008.
- WASADA T, HARRIS V, KAWAI K, HOWARD B, UGER RH: Effects of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. *J Clin Invest* **68**: 1106-1107, 1981.
- WIDEMAN RD, KIEFFER TJ: Glucose-dependent insulintropic polypeptide as a regulator of beta cell function and fate. *Horm Metab Res* **36**: 782-786, 2004.
- WINDPASSINGER C, KROISEL PM, WAGNER K, PETEK E: The human gamma-aminobutyric acid A receptor delta (GABRD) gene: molecular characterisation and tissue-specific expression. *Gene* **292**: 25-31, 2002.
- WORTLEY KE, CHANG GQ, DAVYDOVA Z, FRIED SK, LEIBOWITZ SF: Cocaine- and amphetamine-regulated transcript in the arcuate nucleus stimulates lipid metabolism to control body fat accrual on a high-fat diet. *Regul Pept* **117**: 89-99, 2004.
- YIP RG, WOLFE MM: GIP biology and fat metabolism. *Life Sci* **66**: 91-103, 2000.
- ZACHARIOU V, GEORGESCU D, KANSAL L, MERRIAM P, PICCIOTTO MR: Galanin receptor 1 gene expression is regulated by cyclic AMP through a CREB-dependent mechanism. *J Neurochem* **76**: 191-200, 2001.
- ZHAO AZ, HUAN JN, GUPTA S, PAL R, SAHU A: A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. *Nat Neurosci* **5**: 727-728, 2002.
-